Insys Therapeutics Inc. (fka INSYQ)

[terry hallinan]

Does the Motley Fool enjoy the screams of dying cancer patients with breakthrough pain or is it just discussing those that do?

While Insys stumbles in part because of concerns about opioids, AstraZeneca is benefiting from use of the painkillers. The drugmaker markets Movantik, one of the leading drugs for treating opioid-induced constipation in adults with chronic non-cancer pain.

In reality dying cancer patients have been known to refuse opioids because of paralytic ileus, an extreme constipation from ileus while Insys is even developing another mist form of an FDA-approved drug, Naloxone, with ultra-fast delivery by Insys' patented sublingual spray to hopefully save more of the lives of of many of the overdose victims that die daily.

And there is a treatment for addicts in development and the pharmaceutical grade cannabinoid therapeutics approved and readying for market and more:

http://www.insysrx.com/products/in-development

The Motley Fool's misleading oeuvre:

http://www.fool.com/investing/2016/10/14/how-the-opioid-epidemic-is-changing-2-drugmakers-f.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo

The vultures attacking INSY with far more fanaticism than is exhibited here by the Motley Fool may well succeed in toppling the biotech but there will be some valuable technologies to hit the auction block I reckon.

JMO.

Best, Terry